Skip to main content
Premium Trial:

Request an Annual Quote

ABI Partners with Geospiza, GenomeQuest to Build Bioinformatics Platform for Next-Gen Sequencing

NEW YORK (GenomeWeb News) - Applied Biosystems said today that it has signed formal agreements with Geospiza and GenomeQuest in an effort to develop bioinformatics tools for analyzing and managing data generated by its SOLiD next-generation sequencing system.
 
Under the terms of the agreement with Geospiza, ABI expanded an existing relationship with the firm to ensure that Geospiza’s Finch software, originally designed to automate sequencing workflows for capillary electrophoresis systems, will support the SOLiD system.
 
The agreement with GenomeQuest will ensure that the company’s sequence search platform is integrated with the SOLiD platform.
 
ABI said that it has shared file formats, sample data sets, and analysis pipeline information with both firms so that they can “configure their products, services and capabilities to address customer challenges associated with generating, analyzing, and managing research data in key applications for the SOLiD System.” 
 
The company noted that the SOLiD can generate more than 4 gigabases of sequence data in a single run — far more than the 3 billion bases that comprise the human genome. ABI said that it has partnered with Geospiza and GenomeQuest “to help address managing this vast amount of genomic data by providing complementary services, including the IT infrastructure to manage the data, as well as the ability to process the data and align it to a reference sequence.” 
 
The agreements grew out of ABI’s Software Development Community, which the company originally launched in 2006 to foster third-party software development around its instrumentation platforms. The company expanded the community in 2007 to focus on the challenges of analyzing and managing data generated by next-generation sequencers.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.